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Streptococcus pneumoniae is the major bacterial cause of community-acquired pneumonia,
and the leading agent of childhood pneumonia deaths worldwide. Nasal colonization is an
essential step prior to infection. The cytokine IL-17 protects against such colonization and
vaccines that enhance IL-17 responses to pneumococcal colonization are being developed.
The role of IL-17 in host defence against pneumonia is not known. To address this issue, we
have utilized a murine model of pneumococcal pneumonia in which the gene for the IL-17
cytokine family receptor, Il17ra, has been inactivated. Using this model, we show that IL-17
produced predominantly from γδ T cells protects mice against death from the invasive TIGR4
strain (serotype 4) which expresses a relatively thin capsule. However, in pneumonia pro-
duced by two heavily encapsulated strains with low invasive potential (serotypes 3 and 6B),
IL-17 significantly enhanced mortality. Neutrophil uptake and killing of the serotype 3 strain
was significantly impaired compared to the serotype 4 strain and depletion of neutrophils with
antibody enhanced survival of mice infected with the highly encapsulated SRL1 strain. These
data strongly suggest that IL-17 mediated neutrophil recruitment to the lungs clears infection
from the invasive TIGR4 strain but that lung neutrophils exacerbate disease caused by the
highly encapsulated pneumococcal strains. Thus, whilst augmenting IL-17 immune res-
ponses against pneumococci may decrease nasal colonization, this may worsen outcome
during pneumonia caused by some strains.
Author summary
Streptococcus pneumoniae (the pneumococcus) is an important human pathogen and the
commonest cause of community-acquired pneumonia. The bacterial carbohydrate cap-
sule is a key determinant of virulence and host defence. Pneumonia follows colonization
of the nasopharynx and can spread systemically. The cytokine IL-17, a key regulator of
neutrophil host defence, is important in preventing colonization but its effects on pneu-
mococcal pneumonia are not known. Here, we show that IL-17 has differing roles in host
protection against pneumococcal pneumonia that depend on bacterial strain and capsule
thickness. Pneumococci with thin capsules invade rapidly and IL-17 is protective; in
strains with large capsules that remain in the lungs, IL-17 is detrimental. These strains







Citation: Ritchie ND, Ritchie R, Bayes HK, Mitchell
TJ, Evans TJ (2018) IL-17 can be protective or
deleterious in murine pneumococcal pneumonia.
PLoS Pathog 14(5): e1007099. https://doi.org/
10.1371/journal.ppat.1007099
Editor: Elaine I. Tuomanen, St. Jude Children’s
Research Hospital, UNITED STATES
Received: May 1, 2018
Accepted: May 14, 2018
Published: May 29, 2018
Copyright: © 2018 Ritchie et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: This study was funded by the Medical
Research Council UK through Grant number
G1001998 and the Wellcome Trust (Grant number
094779). The funders had no role in study design,
data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
evade neutrophil killing, and depletion of neutrophils improves outcome following infec-
tion. Thus, neutrophil accumulation within the lung is deleterious in pneumonia caused
by heavily encapsulated pneumococcal strains. Our study provides fresh insight into the
role of IL-17 in host defence against pneumococcal pneumonia, which may also be rele-
vant in other infections caused by encapsulated bacteria that colonize before infection,
such as the meningococcus and Haemophilus influenzae.
Introduction
Streptococcus pneumoniae, or the pneumococcus, is a major cause of pneumonia, meningitis,
sepsis and otitis media, with a highly significant global morbidity and mortality [1, 2]. Initially,
the microbe colonizes the nasopharynx, where it may remain asymptomatically for weeks to
months before eventual clearance [3]. However, following such colonization, in some individu-
als the bacterium can then invade other body compartments, such as the lower respiratory tract
to cause pneumonia, or can spread to blood, myocardium or cerebrospinal fluid [4, 5]. The
microbe has a polysaccharide capsule, which is an essential virulence factor, protecting the
organism against neutrophil phagocytosis and other immune effector mechanisms [6]. The cap-
sular serotype, of which there are over 90 different types, is an important determinant of many
features of pneumococcal colonization and disease [7]. A number of studies have found stable
differences between serotypes in the frequency with which they colonize the nasopharynx com-
pared to their recovery in cases of invasive pneumococcal disease, usually blood [8]. This allows
classification of pneumococci into “invasive” versus “non-invasive strains”, although serotype is
not the only factor influencing invasiveness. Although less likely to cause invasive disease, when
they do invade, these strains are more frequently associated with fatal outcome [9]. Those strains
associated with fatal outcome are more heavily encapsulated in vitro. So-called “non-invasive”
strains such as capsular serotype 3 are, however, commonly isolated from patients with non-bac-
teremic pneumonia [10] or from para-pneumonic effusions [11]. As suggested by Weinberger
et al [9], this may reflect the difficulty with which heavily encapsulated strains may cross epithe-
lial barriers, but by providing protection against neutrophil phagocytosis, the large capsule may
allow persistence in tissues where invasion has occurred, accounting for the increased mortality
produced by such strains.
Conjugate vaccines targeting the polysaccharide capsule provide excellent protection
against nasopharyngeal carriage and have reduced the incidence of invasive disease [12, 13].
These vaccines work by stimulating production of opsonophagocytic antibodies that overcome
the inhibitory effect of the capsule on neutrophil phagocytosis. However, some capsular sero-
types not included in the vaccines have increased in prevalence following population vaccina-
tion [14–16]. This may lead to erosion of vaccine efficacy in the future, so that alternative non-
capsular vaccine targets are being explored [17, 18]. Recent work has highlighted the impor-
tance of cell-mediated immunity in protecting against pneumococcal immunization [19]. In
particular, cytokines of the IL-17 family secreted by cells of the Th17 lineage have been shown
to accelerate clearance of pneumococci in an experimental model of nasopharyngeal coloniza-
tion in mice [20], and confirmed in subsequent studies [21, 22]. Pneumococcal-specific Th17
cells have been detected in humans and mice in several studies and shown to increase in blood
and lung after experimental human nasal colonization with pneumococci [23–25]. The role of
γδ T-cells has also been studied in mouse models of pneumonia [26, 27].
Further studies have examined the role of IL-17 in host defence against pneumonia or other
invasive disease. Mice lacking the IL-23 p19 receptor subunit showed increased bacterial load in
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lung and blood following pulmonary infection and reduced neutrophil influx into the lung [28].
IL-23 is known to be important in maintaining Th17 differentiation [29], suggesting that a rela-
tive lack of IL-17 might be responsible for the decreased neutrophil responses and increased
bacterial load in this study; however, BAL levels of IL-17 following infection were not signifi-
cantly reduced in the IL-23 p19 knockout animals [28]. Mice with prior influenza virus infec-
tion induced type I IFNs that inhibited the recruitment of neutrophils and expression of IL-17,
which correlated with the host’s increased susceptibility to secondary pneumococcal infection
[30]. IL-17 depletion has been shown to negate the protective effect of prior colonization on
experimental murine pneumococcal pneumonia [31], and exogenous IL-17 aids in lung clear-
ance of pneumococci in an allergic inflammation model in mice [32]. Given that neutrophil
recruitment is a major effect of IL-17, we hypothesized that the role of this cytokine in host
defence against a particular pneumococcal strain may critically depend on the resistance of the
strain to neutrophil phagocytosis, and hence on its degree of encapsulation. Here, we investi-
gated the role of IL-17 in host defence against pneumococcal pulmonary infection using mice
lacking the IL-17RA receptor subunit [33]. We show that IL-17 is protective in infection result-
ing from the invasive strain TIGR4 (serotype 4) with relatively thin capsule, but that absence of
IL-17 actually improves outcome in pulmonary infection resulting from two heavily encapsu-
lated strains of serotype 3 and 6B. Thus, whilst induction of a robust IL-17 response to pneumo-
cocci may be beneficial in reducing colonization, for some strains this may lead to a worsening
of pneumonia and clinical outcome.
Results
Models of pneumonia with pneumococcal strains of different capsule
thickness
In vitro capsular thickness of different pneumococcal strains is related to outcome of infection
[9]. To explore the role of IL-17 in host defence against pneumococci with different degrees of
encapsulation, we set up murine models of pulmonary infection with two strains of pneumo-
cocci differing in their capsular thickness and invasiveness potential. We chose the serotype 4
strain TIGR4 as a representative of an invasive phenotype with relatively low capsular thick-
ness and a clinical serotype 3 isolate (SRL1) as a representative strain with high capsular thick-
ness and low invasive potential. We confirmed these isolates differed in their capsule thickness
as expected (Fig 1), with SRL1 having an average bacterial area ~60% larger than TIGR4.
Groups of mice were infected with the different strains by intranasal inoculation under light
anesthesia, resulting in aspiration of the administered inoculum into the lower airways. Animals
were culled at fixed time points after infection to determine bacterial burden at different sites
and associated cytokine responses. Following infection with TIGR4, there was a relatively rapid
clearance of bacteria from bronchoalveolar lavage fluid (BALF) and subsequent transit to blood
and the pleural space (Fig 2A–2C). This was in marked contrast to the dynamics of bacterial
transit after infection with SRL1, which showed a steady accumulation in BALF and delayed
transit to blood and pleural space (Fig 2A–2C). IL-17A peaked at 12 hours in BALF with TIGR4
but was delayed to 24 hours following SRL1 infection. Correspondingly, lung neutrophils sh-
owed a peak accumulation 12 hours after TIGR4 infection but a slower rise to reach a plateau
after SRL1 infection (Fig 2D and 2E). Histology of the lung after infection with TIGR4 showed a
patchy bronchopneumonia with peribronchial accumulations of neutrophils (Fig 2F and 2G).
In contrast, after SRL1 infection, areas of dense consolidation were evident composed of larger
aggregates of neutrophils (Fig 2F and 2G). Thus, taken together these data show that these dif-
ferent pneumococcal strains produce a different pattern of infection: TIGR4 results in a patchy
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pneumonia with rapid transit through the lung into blood and pleural space, while SRL1 pro-
duces a dense lobar consolidation with late transit to extra-pulmonary sites.
Role of IL-17 in host defence against pulmonary infection with an invasive
pneumococcal strain (TIGR4) of relatively low capsular thickness
To test the role of IL-17 family cytokines in this model of pneumococcal pulmonary infection,
we infected groups of mice with a targeted deletion of the Il17ra gene, as well as with control
wild type littermates. Firstly, we infected animals with the invasive pneumococcal strain
TIGR4. At a dose of 106 bacteria inoculated per animal, we produced a mild infection in wild
Fig 1. Capsular size of bacterial isolates. Bacteria were visualized using electron microscopy and fluorescence microscopy with dextran exclusion. (A)
Representative transmission electron microscopy images of SRL1 and TIGR4 following fixation using ruthenium red and lysine-acetate. (B) Capsular area of
SRL1 and TIGR4 as visualized by electron microscopy. (C). Area of dextran exclusion per bacterial cell. (B-C) Line shows median. (Significant difference by
Mann Whitney test,  p< 0.01, , p< 0.001).
https://doi.org/10.1371/journal.ppat.1007099.g001
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Fig 2. Course of infection caused by TIGR4 and SRL1. C57Bl/6 mice were infected with either TIGR4 (5 x 106 cfu/
mouse) or SRL1 (106 cfu/mouse) by intranasal inoculation and culled at pre-determined intervals. Bacteria were
enumerated in BALF (A), pleural aspirate (B) and blood (C). Concentration of IL-17A in BALF (D) and MPO in lung
(E) were determined. (F) H&E tissue sections of mice infected for 48 hours at original magnification of x4. G.
Immunohistochemistry using the neutrophil marker Ly-6G at an original magnification of x40. Points are means from
three animals; bars show SEM. Representative of two independent experiments.
https://doi.org/10.1371/journal.ppat.1007099.g002
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type animals, with over 90% survival (Fig 3A, n = 15 animals). In the Il17ra knockout (KO)
animals, there was a significantly increased mortality, with only 9 out of 15 animals surviving
at the end of the observation period (Fig 3A, n = 15 animals). Known targets of IL-17 in lung
were quantified by RT-PCR and showed large upregulation in the infected wild type animals
that was virtually abolished in the infected IL-17RA knockout mice (S1 Fig).
The increased mortality in the IL-17RA knockout animals was associated with a significant
increase in the recovered viable bacteria in blood at 48 hours after infection (Fig 3B). Recov-
ered bacteria in BALF at 24 hours were at a low level and not significantly different between
the WT and Il17ra KO animals (Fig 3C); however, blood and BALF neutrophil counts at this
same time point were significantly lower in the Il17ra KO mice (Fig 3D and 3E). Histology of
lung 24 hours after infection showed marked differences between the groups of animals. The
aggregates of neutrophils surrounding airways were significantly decreased in size and number
in the WT animals compared to the Il17ra KO mice (Fig 3F and 3G). Both sets of animals lost
weight during the experiment; this was significantly less in the Il17ra KO animals (S2 Fig). A
measure of lung edema, the wet/dry lung weight ratio, was not different between the WT and
Il17ra KO animals (S3 Fig).
Role of IL-17 in host defence against pulmonary infection with a highly
encapsulated non-invasive pneumococcal strain (SRL1)
The same experimental protocol was adopted to determine the course of infection of WT and
Il17raKO animals with the highly encapsulated non-invasive serotype 3 strain of pneumococ-
cus, SRL1, using the same inoculum as with TIGR4 (106 cfu/mouse). The Il17ra KO mice
showed a clear and significant survival advantage following infection with this strain (Fig 4A),
the reverse of the result following infection with the invasive TIGR4 strain. WT animals
became bacteremic at earlier time points following infection compared to the Il17ra KO ani-
mals (Fig 4B). Bacterial counts within BALF from animals culled at 24 hours after infection in
separate experiments were not significantly lower in Il17raKO animals compared to controls
(Fig 4C). However, at 7 days after infection in surviving animals from the experiments shown
in Fig 4A, in 7 of the 10 surviving Il17raKO animals significant numbers of bacteria could be
recovered from their BALF, despite the animals remaining completely healthy and without
any sign of ongoing infection (Fig 4D). No surviving WT animal had any residual bacteria
within BALF.
Numbers of neutrophils in both blood and BALF in infected animals culled at 24 hours
after infection were significantly lower in the Il17ra KO animals (Fig 4E and 4F). The weight
of WT animals showed a steady decline after infection to a steady low level that was main-
tained over the 7 days of the experiment (Fig 4G). In contrast, Il17raKO animals showed a
much lower initial weight loss and a partial recovery 72 hours after infection (Fig 4G). At 24
hours after infection wet/dry lung weights were significantly higher in WT animals, consistent
with increased pulmonary edema in these mice compared to the Il17ra KO animals (Fig 4H).
Histological analysis of lung tissue in animals culled 24 hours after infection showed large
areas of confluent consolidation in WT animals, largely composed of neutrophils (Fig 4I). In
Il17raKO animals, areas of consolidation were much smaller; these differences were significant
(Fig 4I and 4J).
Neutrophil phagocytosis and killing of TIGR4 and SRL1
We hypothesized that the differences in outcome between WT and Il17ra KO mice in their
response to the different pneumococcal strains were due to the effectiveness of neutrophil
clearance of bacteria. To test this hypothesis, we compared the ability of neutrophils in vitro to
IL-17 in pneumocccal pneumonia
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007099 May 29, 2018 6 / 25
Fig 3. Infection of Il17ra KO mice with TIGR4. C57Bl/6 mice (10–16 per group) were infected with 106 cfu/mouse
TIGR4 by intranasal inoculation and either observed for the course of the infection or culled after 24 hours. (A) Kaplan
Meier plot of survival for WT (solid line) or IL-17RA-/- (dashed line), P< 0.001 (log rank test). (B) Blood and (C)
BALF bacterial counts 24 h after infection. (D) blood and (E) BALF neutrophil counts 24 h after infection. (F) Lung
inflammation measured by blinded assessment of hemotoxylin and eosin (HE) stained sections. (B-E), each point
shows the value from an individual animal; line is median. Differences between groups were assessed by Mann
Whitney test;  p<0.05,  p< 0.01, , p< 0.001, ns, not significant. (G) Representative areas of inflamed lung from
HE stained sections and neutrophil immunohistochemistry (Neutrophil IHC) stained lung at 24 h after infection.
Original magnification x40. All data representative of two independent experiments.
https://doi.org/10.1371/journal.ppat.1007099.g003
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take up and kill the two pneumococcal strains. Using a killing assay as described in the Meth-
ods in whole complement containing serum, we measured the rate constant of neutrophil
clearance of the different strains (Fig 5A). This was consistently significantly lower for clear-
ance of SRL1 compared to TIGR4. Direct measures of phagocytosis by two different methods
also showed a marked reduction in neutrophil uptake of SRL1 compared to TIGR4 (Fig 5B
and 5C). Pneumococci induce neutrophils to form neutrophil extracellular traps (NETs). Both
TIGR4 and SRL1 induced NET formation (Fig 5D and 5E). SRL1 induced more traps than
TIGR4 and these were significantly larger (Fig 5F and 5G). Pneumococci are reported to be
relatively resistant to NET mediated killing, but NET formation has been reported to enhance
Fig 4. Infection of Il17ra KO mice with SRL1. C57Bl/6 mice (9–11 per group) were infected with 106 cfu/mouse SRL1 by intranasal inoculation and either
observed for the course of the infection or culled after 24 hours. A. Kaplan Meier plot of survival for WT (solid line) or IL-17RA-/- (dashed line) (P< 0.01, log
rank test). (B) Blood and (C) BALF bacterial counts 48 after infection. (D) BALF bacterial counts from mice which survived infection with SRL1 (pooled from
multiple experiments). (E) Blood and (F) BALF neutrophils. (G) Weight of animals following infection; open circles IL-17RA KO and closed circles WT. Each
point is the mean (n = 9–11); error bar is SEM. Difference between the groups is significant, (p< 0.001, two way ANOVA). (H) lung wet/dry mass ratio at 24
hours post infection. (I) Representative areas of inflamed lung from HE stained sections and neutrophil stained lung. (J) Lung inflammation measured by
blinded assessment of HE stained sections. Significance levels as in Fig 2. All data representative of two independent experiments.
https://doi.org/10.1371/journal.ppat.1007099.g004
IL-17 in pneumocccal pneumonia
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007099 May 29, 2018 8 / 25
Fig 5. In vitro neutrophil phagocytosis, killing and NET formation. (A) A constant of killing was calculated using the method described by Hampton (MOI 1). The
paired constants for each strain derived from 3 independent experiments are shown; differences between the two strains were significant (paired t-test, p = 0.01). (B)
Fluorescent pneumococci (MOI 10) were cultured with mouse neutrophils and visualized by flow cytometry at the indicated times after bacterial addition. (C) as (B)
but associated bacteria (closed bars, SRL1, open bars TIGR4) enumerated by fluorescence microscopy. Bars are means of at least 50 determinations; error bars are
SEM. Differences between the strains are significant, p< 0.001, two-way ANOVA). (D-F) NET formation by neutrophils was assessed by fluorescence microscopy
(MOI 10). (D) Representative confocal images of neutrophils forming NETs (blue: S. pneumoniae, green: anti-neutrophil elastase, red: sytox orange). (E) Percentage
of neutrophils in NETs following incubation with indicated strains or PMA. Bars are means of at least 4 separate low power fields; error bars are SEM. Significant
differences between the groups were determined by t tests with Tukey’s post hoc correction;  p<0.01,  p< 0.001. (F) mean NET size formed by TIGR4 and
SRL1. Bars as in (E). Difference between the strains is significant, p< 0.05, t test. B-F representative of two independent experiments.
https://doi.org/10.1371/journal.ppat.1007099.g005
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development of pneumococcal otitis media [34]. The enhanced NET formation produced by
SRL1 may thus be important in retaining this microbe in lung; this is considered further in the
Discussion.
Neutrophil depletion increases survival after SRL1 infection
Levels of neutrophils in the lungs of SRL1 infected animals are sustained (Fig 2) and are less
able to kill this strain of pneumococcus compared to TIGR4 (Fig 5). Given that a major effect
of IL17 is to enhance neutrophil production and mobilization, we hypothesized that the differ-
ing effects of IL17 on outcome from infection with these two strains manifest in Figs 3 and 4
could be due to neutrophils enhancing survival in infection with the invasive TIGR4 serotype
but increasing mortality in infection with the non-invasive SRL1 strain. To test this directly,
we depleted neutrophils in mice using a cytotoxic highly specific antibody directed against the
neutrophil marker Ly6G, that does not cross react with other leucocytes [35]; animals were
then infected with the different pneumococcal strains.
In animals infected with TIGR4, the anti-Ly6G treatment produced a significant reduction in
peripheral neutrophil counts following infection, largely abrogating the rise seen in the control
isotype treated mice (Fig 6A). Survival following infection showed a trend towards decreased sur-
vival in the anti-Ly6G treated group although this did not reach statistical significance (Fig 6B).
However, the time to death in the two groups showed a statistically shorter interval in the anti-
Ly6G treated mice (Fig 6C). Bacteremia also showed a trend towards earlier onset and increased
levels in the anti-Ly6G animals, and clinical scores were also worse in this group; however, nei-
ther of these differences reached statistical significance (Fig 6D and 6E). In addition, there was a
trend towards greater weight loss following infection in the neutrophil-depleted animals.
In animals infected with the SRL1 strain, the anti-Ly6G treatment produced a sustained
reduction in peripheral neutrophils (Fig 6F). Compared to the isotype-treated controls, the
mice that received the anti-Ly6G antibody had a clear and significant survival advantage (Fig
6G). They also had a statistically significant reduction in clinical score after infection (Fig 6H)
and a trend towards decreased weight loss after infection.
Improvement in outcome of neutrophil-depleted WT mice after SRL1 infection shows that
neutrophils mediate adverse effects after infection with this highly capsulated strain. IL-17
induces neutrophil recruitment and activation; this may thus account for the improved out-
come in Il17ra KO mice. However, IL-17 also induces other effects, such as production of anti-
microbial peptides and synergy with other inflammatory cytokines. In order to determine the
relative importance of these IL-17-mediated neutrophil and non-neutrophil effects, we exam-
ined the effects of neutrophil depletion in Il17ra KO animals infected with SRL1. As before,
anti-Ly6G antibody treatment reduced peripheral blood neutrophils (Fig 7A). In contrast to
results in WT mice, in the Il17ra KO animals, outcome and clinical scores were significantly
worse in the neutrophil depleted group (Fig 7B and 7C). These results are considered further
in the Discussion.
Cellular sources of IL-17 within infected lung
We wished to ascertain the cellular origins of IL-17 in the lung following pneumococcal infec-
tion, and to determine whether there were any differences between the pneumococcal strains.
We used flow cytometric analysis of cells from lung homogenates stained with a panel of anti-
bodies to identify a variety of cell lineages as set out in the Methods. Cells from control, unin-
fected animals were analyzed together with those from animals 48 hours after infection with
TIGR4 and SRL1. We found that because the inflammatory infiltrate had a patchy localization
within infected lungs, determination of absolute numbers of the different cell types within the
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lung varied very considerably between different experimental animals. However, we were able
to compare the relative proportion of each cell type before and after infection that could pro-
duce IL-17 after ex vivo stimulation with PMA and ionomycin and staining for intracellular Il-
17A (Fig 8A). This determination was not influenced by differential recovery of inflammatory
cells between animals. The cell type most likely to produce IL-17A following stimulation was
γδ TCR+ cells, but there was no change between infected and uninfected mice. The only signif-
icant change noted was a reduction in the proportion of neutrophils capable of synthesizing
intracellular IL-17 following infection, although the absolute numbers of these cells are very
low. As these cells are stimulated to produce IL-17 ex vivo, it does not necessarily reflect their
activity during an infection. To address this question, we administered brefeldin A to infected
animals prior to harvesting lung cells to allow accumulation of IL-17 in those cells actively pro-
ducing this cytokine during infection. Cell homogenates were then analyzed for intracellular
IL-17 production without further stimulation. The only cell lineage that produced IL-17A
under these conditions were γδ T cells, showing a rise in intracellular IL17A+ cells from 0.58%
to 3.8% following infection (Fig 8B). To confirm that γδ T cells were a significant source of IL-
17A during infection, we administered an antibody that depletes γδ T cells 6 hours before
infection. We then assayed IL-17A in BALF 6 hours after infection in these animals and those
that received an isotype control (Fig 8C). IL-17A production in BALF was largely abrogated in
animals in which γδ T cells were depleted compared to the isotype controls. Thus, the majority
of IL-17 produced locally within the lung following pneumococcal infection in this model
originates from γδ T cells.
Role of IL-17 in nasopharyngeal colonization of mice with TIGR4 and
SRL1
We examined the effect of IL-17 on nasopharyngeal colonization by TIGR4 and SRL1. 7 days
after inoculation of these strains into the anterior nares, there were significantly higher num-
bers of bacteria recovered from the nasopharynx of IL17ra KO mice compared to WT mice for
both the TIGR4 and SRL1 strains (Fig 9). Thus, the deleterious role of IL-17 following pulmo-
nary infection with SRL1 is not seen with nasopharyngeal colonization, where IL-17 is protec-
tive for both TIGR4 and SRL1.
Role of IL-17 in host defence against pulmonary infection with an
additional highly encapsulated non-invasive pneumococcal strain SRL2
(serotype 6B)
Although capsular phenotype is a major determinant of outcome following infection, other
factors could contribute to the observed differences between TIGR4 and SRL1. We thus
explored the effects of infection of a TIGR4 capsule switched mutant that had been engineered
to express capsule type 3, the capsular type of SRL1 [36]. We found this strain was avirulent
Fig 6. Infection with TIGR4 or SRL1 following depletion of neutrophils. C57Bl/6 mice (20 per group) were infected with 106 cfu/mouse of TIGR4
(A-D) or SRL1 (E-F) by intranasal inoculation 24 hours after intraperitoneal inoculation of 500 μg antibody 1A8 (anti-Ly6G) or isotype matched control
and observed for the course of the infection. (A) peripheral blood neutrophil counts following treatment with isotype control (filled circles) or anti-Ly6G
(open circles) at indicated times following infection. Differences (Mann Whitney test) were not significant (NS) or significant (, p< 0.05, ,
p< 0.001) (B) Isotype control treated mice (solid line) and neutrophil depleted mice (dashed line) had similar survival (A, P = 0.09, log rank test). (C)
Median survival time among neutrophil depleted mice; each point is an individual animal, line is median. Differences are significant (, Mann Whitney
test, p = 0.01). (D) bacteremia and (E) clinical score between isotype treated mice (solid circles) and neutrophil depleted mice (open circles). Differences
are not significant. (F) as (A) following infection with SRL1 (G) Outcome following SRL1 infection. Isotype control treated mice (solid line) had
impaired survival compared to neutrophil depleted mice (dashed line) (p = 0.02, log rank test). (H) Clinical score in neutrophil depleted mice (open
circles) compared to isotype treated mice (solid circles). Differences between the groups are significant (p = 0.01, 2-way ANOVA corrected for repeated
measures).
https://doi.org/10.1371/journal.ppat.1007099.g006
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Fig 7. Infection with SRL1 in Il17ra KO mice following depletion of neutrophils. Il17ra KO mice were infected with
106 cfu/mouse of SRL1by intranasal inoculation 24 hours after intraperitoneal inoculation of 500 μg antibody 1A8
(anti-Ly6G) or isotype matched control and observed for the course of the infection. (A) peripheral blood neutrophil
counts following treatment with isotype control (filled circles) or anti-Ly6G (open circles) at 24 hours following
IL-17 in pneumocccal pneumonia
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when given by nasal inoculum in doses up to 1 x 107 per mouse, and could not be recovered
from blood following intraperitoneal inoculation of mice. Loss of virulence of capsule switched
mutants of the pneumococcus has been documented previously [37–39].
To explore further the link between capsule type and IL-17 mediated host immunity, we
determined whether another highly encapsulated non-invasive strain would also show a sur-
vival benefit following infections in Il17raKO mice. We selected another train, SRL2, which
was a serotype 6B capsular phenotype, known to be a relatively non-invasive strain with a large
capsule [9]. We confirmed the relatively large size of the capsule compared to TIGR4 using the
same methods as in Fig 1.
Infection with SRL2 produced an extensive pneumonia with large areas of confluent consoli-
dation as seen with infection with SRL1 (Fig 10A). There was a clear and significant difference
in survival between WT and Il17ra KO animals, with none of the Il17ra KO animals dying fol-
lowing infection, compared to a 40% mortality in the WT animals (Fig 10B). There was a trend
towards decreased weight loss in the Il17ra KO animals following SRL2 infection (Fig 10C) and
significantly lower clinical scores in this group compared to the infected wild type animals (Fig
10D). As observed with the other pneumococcal infections, blood neutrophils were significantly
reduced in the Il17ra KO animals after infection (Fig 10E). In the surviving animals 7 days after
infection, all of whom showed no evidence of any ongoing infection, we found 60% of the
Il17raKO mice had detectable levels of SRL2 in BALF, a similar observation to the surviving
Il17ra KO mice following SRL1 infection.
Discussion
We have shown here that protective versus harmful effects of IL-17 in the innate immune
response to acute pneumococcal infection in a murine model are critically dependent on pneu-
mococcal strain. IL-17 is protective against pulmonary infection with TIGR4, a representative
invasive strain of relatively low capsular thickness, but has an adverse effect on outcome fol-
lowing infection with 2 separate highly encapsulated strains (SRL1 and SRL2) that are repre-
sentative of strains of lower invasive potential. Since neutrophil depletion improved survival
following infection with these strains, we believe that the deleterious effect of IL-17 against
these strains in this model is mediated by neutrophils. This is also supported by the interac-
tions of purified neutrophils with TIGR4 and SRL1, which show that the highly encapsulated
SRL1 strain is better able to avoid neutrophil uptake and killing compared to TIGR4. Neutro-
phil-mediated damage has been implicated as a key pathogenic factor in adult respiratory dis-
tress syndrome [40] and contributing to tissue damage by bacterial and nematode infection
[41, 42]. Neutrophil depletion enhanced survival in a model of pneumococcal infection caused
by a non-hemolytic serotype 8 strain [43]. We propose that extensive neutrophil accumulation
as seen in Fig 4, mediates enhanced tissue damage following pulmonary infection with highly
encapsulated pneumococcal strains, allowing enhanced growth and passage of bacteria out of
the lung and increasing mortality.
Capsular phenotype is an important determinant of many different aspects of pneumococ-
cal pathogenicity. Here, we have developed a murine model of pneumonia that reflects the
clinical course of pneumococcal infection by different serotypes. TIGR4 (serotype 4)
infection. Each point is from an individual animal; line indicates median. Difference is significant (, p< 0.01, Mann
Whitney test) (B). Kaplan Meir plot of survival of infected mice. Isotype control treated mice (solid line) had improved
survival compared to neutrophil depleted mice (dashed line) (p = 0.017, log rank test). (C) clinical score between
isotype treated mice (solid circles) and neutrophil depleted mice (open circles) Differences are significant between the
groups (p < 0.0001, 2-way ANOVA).
https://doi.org/10.1371/journal.ppat.1007099.g007
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Fig 8. Cellular sources of IL-17A in pneumococcal infection. (A) Proportion of cells staining positive for IL-17
following stimulation with PMA and ionomycin in the presence of Brefeldin 48 hours post infection. Bars are means of
6 determinations; error bars are SEM. Differences between groups were tested by one-way ANOVA and where
significant differences from the uninfected group tested by Dunnett’s test. , p< 0.05, , p< 0.01. (B) Flow cytometry
of In vivo expression of IL-17 by gamma delta T lymphocytes from animals treated with Brefeldin A 6 hours prior to
infection and culled 6 hours post infection. Shaded area is isotype control staining. Representative of 2 independent
experiments. (C) BALF IL-17A concentration in animals treated with a gamma delta T cell depleting antibody (anti-
GDTCR) or isotype control 24 hours prior to infection and culled 12 hours after infection. Each symbol is an
individual animal; line is the median. Difference between the groups is significant (Mann Whitney test, p = 0.008).
https://doi.org/10.1371/journal.ppat.1007099.g008
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represents an ‘invasive’ strain that is less commonly found as a colonizing strain compared to
its isolation as an invasive organism, that typically would imply isolation from blood or csf.
SRL1 is a representative relatively “non-invasive” strain, with opposite properties. In our
model, TIGR4 produces a patchy bronchopneumonia but transits rapidly through the lung to
invade blood. SRL1 infection results in much more extensive lung consolidation and only
invades blood relatively late. Most human studies of pneumococcal infection rely on definitive
diagnosis by blood culture and will only identify a minority of pneumonias caused by the
pneumococcus. However, the differences in the phenotype of infection produced by these
strains in the model described here is certainly consistent with available data from human
studies.
Factors other than capsule will impact on pathogenicity of different pneumococcal strains.
We attempted to test the effect of capsular phenotype alone, by examining the outcome of infec-
tion with a TIGR4 capsule switch mutant expressing the type 3 capsule. However, this strain
was not virulent in our model. This lack of virulence in capsule switch mutants has been
described in previous reports [37–39]. These studies suggest that capsular type imposes restric-
tions on expression or accessibility of key virulence determinants, such that changing capsular
type may attenuate the virulence of a specific pneumococcal strain. Co-evolution of capsule and
virulence determinants thus ensures optimal expression of these determinants in a specific
Fig 9. Nasal colonization with TIGR4 or SRL1 in IL-17RA-/- mice. Bacterial counts in nasal wash enumerated 24
after inoculation. Line shows median value; differences are significant by Mann Whitney test, , p< 0.05.
https://doi.org/10.1371/journal.ppat.1007099.g009
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Fig 10. Infection of IL-17RA-/- mice with SRL2. (A) Representative area of inflamed lung from H&E stained lung sections of mice infected with SRL2. (B)
Kaplin-Meier plot of survival following infection of wild type (solid line) or IL-17RA-/- (dashed line) mice with SRL2. Survival of IL-17RA-/- mice was
improved (logrank test, p = 0.03). (C) Weight following infection in IL-17RA-/- mice (open circles) and control mice (closed circles). Points are means
(n = 10); error bars are SEM. Differences between the groups were not significant (two-way ANOVA, p = 0.06). (D) as (C) but showing clinical score.
Difference between the groups was significant (two-way ANOVA, p< 0.001). (E) peripheral blood neutrophil percentage in WT and IL-17RA-/- mice 24 h
after infection. Line shows median value. Closed symbols are animals that survived to the end of the 7 day experiment. Differences between the groups are
significant (Mann Whitney test, p = 0.03). (F) BALF bacterial counts from mice that survived infection with SRL2. Line shows median value. Differences
between the groups are significant (Mann Whitney test, p = 0.01). Animal shown in blue had mild clinical illness; the remainder had no clinical signs of
infection.
https://doi.org/10.1371/journal.ppat.1007099.g010
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capsule type. Direct comparison of infection with SRL1 and 2, both highly encapsulated strains,
shows outcome is improved in the absence of IL-17 signaling, in contrast to the results seen
with TIGR4, a strain with relatively thin capsule. We also show that neutrophil depletion attenu-
ates the effects of infection with the type 3 capsular expressing strain and thus propose that IL-
17 exerts a deleterious effect in infection with SRL1 and SRL2 because of IL-17-mediated neu-
trophil damage. Other factors might contribute to the observed difference in the effect of IL-17
on infection with these different strains, but our data are consistent with a hypothesis that the
thick capsular phenotype leads to IL-17dependent neutrophil accumulation in the lung, with
consequent neutrophil-mediated lung damage and escape of the microbe into the systemic
circulation.
There is, however, a balance between the beneficial effects of neutrophils in bacterial clear-
ance and potential deleterious effects when present in excess. This is demonstrated in our
experiments analysing the effects of neutrophil depletion in Il17ra KO mice. Compared to the
effects on neutrophil depletion in WT mice, in mice lacking IL-17 signalling, neutrophil deple-
tion worsened outcome. We propose that the most likely explanation of these results is that
there is a critical level of neutrophils below which effective bacterial clearance is severely com-
promised. Thus, in the Il17ra KO animals, neutrophil recruitment and activation is attenuated
to an extent that ameliorates pulmonary disease, but prevents bacterial escape into the systemic
circulation and subsequent severe disease. When neutrophil levels are depleted further in the
Il17ra KO animals, they are no longer able to restrict the infection and animals thus develop
severe disease and die. An alternative view would be that non-neutrophil effects of IL-17
account for worse outcome in SRL1 infection. We do not favour this interpretation, as it
would be difficult to understand how IL-17 effects such as induction of antimicrobial peptides
could worsen outcome, although we cannot totally exclude a role for non-neutrophil effects of
IL-17 on outcome in SRL1 and 2 infection.
BALF pneumococcal bacterial counts were about 2 log higher in WT SRL1 infected animals
compared to TIGR4, in keeping with a view that the larger type 3 capsule favours retention
within the lung and hence the ‘non-invasiveness’ of this serotype in human studies. This is in
comparison to TIGR4, a representative of an ‘invasive’ human phenotype with thinner capsule.
In SRL1 infection, lack of IL-17 effects resulted in lower transit of the microbe into blood but
without a concomitant rise in pneumococcal bacterial counts in BALF. We propose that this
reflects the ability of non-IL-17 innate immune mechanisms to keep SRL1 infection within the
lung in check. This is supported by the observation that in the absence of IL-17 RA, significant
numbers of viable SRL1 and SRL2 bacteria could be recovered from lungs of completely healthy
mice. This suggests that innate mechanisms other than those driven by IL-17 can keep SRL1
and SRL2 infection controlled but not eradicated within the lung. In contrast, no animals that
survived TIGR4 infection had evidence of viable bacteria remaining within their lungs. The
large capsules of SRL1 and SRL2 thus would appear to favour retention of the organism within
the lung, which in the absence of IL-17 mediated killing results in viable bacteria remaining but
not causing further disease. Possible mechanisms for this retention of highly encapsulated
strains could be an inability to traverse the alveolar epithelial barrier or retention by NETs as
shown in this study. Further work will be required to define the exact mechanisms involved.
IL-17 mediated protection against pneumococcal colonization has been demonstrated in a
number of studies [25, 31]. Thus, a robust pneumococcal-specific IL-17 response following
vaccination with a whole-cell or recombinant pneumococcal vaccine has been proposed to be
beneficial in providing host defence [17, 23]. However, while IL-17 is instrumental in prevent-
ing nasopharyngeal colonization, the role in disease states is less clear. There is strong evidence
that antibody mediated immunity is the dominant protective mediator in bacteremia [44]. In
our study, IL-17 reduced the likelihood of bacteremia in TIGR4 infection but did not affect
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disease progression in bacteremic animals. The role of IL-17 in pulmonary infection was
recently explored in the context of acquired immunity [31]. IL-17 accelerated lower respiratory
tract clearance of a serotype 19F strain of relatively low virulence in a manner that was partially
dependent on neutrophils. Our data support this finding that IL-17 is required to efficiently
clear highly encapsulated pneumococci from the lower airways. However, in severe infection
the deleterious effect of neutrophil recruitment outweighs benefit and worsens outcome. Thus,
the data presented here strongly suggest that, under some circumstances, disease from highly
encapsulated strains will be exacerbated by IL-17. How far these results might be applicable to
the role of IL17 in human pneumococcal pneumonia is not clear. Rare families with absence of
IL17RA or other elements of the IL17 axis have been described. The main infectious complica-
tion experienced is that of chronic mucocutaneous candidiasis, but in a study of 21 patients
with inherited IL-17RA deficiency, 3 experienced recurrent lobar pneumonia [45]. Given that
the pneumococcus is the commonest cause of lobar community-acquired pneumonia, this
suggests that IL-17RA is key in human host defence against pneumococcal disease. However,
not enough data exist to draw any conclusions about the effects of different capsular types on
the outcome of pneumococcal infection in such patients.
Materials and methods
Bacterial strains
TIGR4 (Serotype 4) is a clinical isolate that has been previously described [46]. SRL1 (Serotype
3) and SRL2 (Serotype 6B) were obtained from the Scottish Haemophilus, Legionella, Menin-
gococcus and Pneumococcus Reference Laboratory. The TIGR4 capsular switch mutant to
type 3 was kindly provided by Professor Jerry Brown, University College London. Quantifica-
tion of bacteria was performed by serial dilution onto 5% horse blood agar plates.
Animals and models of colonization and disease
All mice used were on a C57Bl/6 background. IIl17ra KO mice were obtained from Jay Kolls
(University of Pittsburgh). Mice were housed in pathogen free conditions at the University of
Glasgow and maintained according to standard procedures. All research was conducted in
accordance with institutional guidelines and in accordance with Home Office regulations.
Models of pulmonary infection [47] and colonization [48] were performed as previously
described. Briefly, bacterial stocks were prepared by passage through mice and kept frozen for
use in infection models. Mice were inoculated via the intra-nasal route with light gaseous
anaesthesia in models of pulmonary infection and gentle immobilization in the absence of
anaesthesia for colonization models. Mice were monitored using a standardized scoring sys-
tem and culled either at a pre-determined time point or if the severity score reached the speci-
fied level. In some experiments, mice were administered the monoclonal antibodies 1A8 [35]
(mouse neutrophil specific antibody to Ly6G; 500 μg, Bio-X-cell), UC7-13D5 [49] (mouse γδ
cell specific antibody to murine γδ T cell receptor; 100 μg, eBioscience) or appropriately
matched isotype control by intraperitoneal injection 24 hours prior to the start of the experi-
ment. In other experiments, mice were administered 250 μg Brefeldin A by intraperitoneal
injection 6 hours prior to being culled.
Blood was obtained by tail vein puncture. Bronchial and pleural lavage were performed as
previously described. Neutrophil counts from these fluids were obtained by lysing red blood
cells and staining neutrophils with anti-Ly6G (RB6-8C5, PE or eFluor605NC, eBioscience)
before gating on side scatter+Ly6G+. IL-17A ELISA was conducted using the Ready,Set,Go kit
(eBioscience) according to the manufacturer’s instructions.
IL-17 in pneumocccal pneumonia
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007099 May 29, 2018 19 / 25
Lung myeloperoxidase activity was quantified by placing a lobe of lung in 50 mMol KH2PO4
with 0.5% hexadecyltrimethylammonium bromide in ddH2O, homogenizing with a tissue
grinder and lysing by sonication. MPO activity was then determined as previously described
[50]. To determine the wet/dry ratio, a single lobe of lung was blotted on tissue paper to remove
surface fluid and carefully weighed. The lung was then placed in an oven at 60˚C for 48 hours
and the desiccated lung weighed again.
Lung homogenates were prepared by perfusing the lungs with ice cold saline via the right
ventricle before removing the lungs and cutting them into small pieces. Homogenisation was
performed enzymatically in IMDM media supplemented with 1% foetal bovine serum, 50 μg/ml
DNAse and 0.65 units/ml liberase TM (Roche, CH) followed by passing fragments through a
40 μm cell strainer. After lysing red cells and washing, cells were prepared for flow cytometry
according to the manufacturer’s instructions. Where indicated, cells were incubated with media
containing phorbol 12-myristate 13-acetate (PMA) (50 ng/ml), ionomycin (1 μg/ml) and Brefel-
din A (5 μg/ml). Cells were then incubated for 6 hours at 37˚C. Cells were stained with FVD 750
(eBioscience) before antibody staining. Antibodies used during flow cytometry were: anti-Ly6G
(RB6-8C5, PE or eFluor605NC, eBioscience), anti-B220 (RA3-6B2, PE-Cy7, Biolegend), anti-
CD3 (17A2, PE-Cy7, Biolegend), anti-CD4 (RM4-5, PerCP-Cy5.5 or eFluor605NC, eBioscience)
and anti-γδTCR (UC7-13D5, A. fluor 488, Biolegend). Anti-IL-17A (TC11-18H10.1, PE,
eBioscience) was used following fixation and permeabilization according to the manufacturer’s
instructions. Cells were re-suspended in a buffer containing PBS supplemented with 2mmol/l
EDTA, 10% foetal calf serum (FCS) and 0.09g/l sodium azide and analyzed on an ADP-CyAN
flow cytometer (Beckman Coulter) or LSR II (BD Biosciences).
For neutrophil immunohistochemistry lungs were fixed in zinc salt fixative [51] for 48
hours before tissue processing into paraffin blocks. After cutting and rehydration, endogenous
peroxidase was blocked by immersion in a 3% H2O2 in PBS for 30 minutes and endogenous
biotin blocked using an Avidin/Biotin blocking kit (Vector Laboratories) according to the
manufacturer’s instructions. After blocking and permeabilization, sections were incubated
overnight at 4˚C with 500 ng/ml anti-Ly-6G (1A8, eBioscience) or matched isotype control.
The following day, sections were washed before incubation for 1 hour at room temperature
with secondary antibody and subsequently washed again. Sections were then incubated for 30
minutes at room temperature with avidin/biotinylated peroxidase complex (VECTASTAIN
ABC, Vector Laboratories) and washed. Sections were then incubated at room temperature
with 3,3’-diaminobenzidine (DAB, Vector Laboratories) until adequate colour change
occurred. Sections were rinsed in water before nuclei were stained for 5 minutes with methyl
green solution and rinsed in distilled water. Sections were then dehydrated rapidly through
serial alcohols, cleared in two changes of xylene for 5 minutes each and then analyzed.
RT-PCR
Immediately after dissection, lungs were placed in RNA later solution (Life Technologies) and
frozen at -80˚C until use. After gentle thawing, lungs were transferred into a 2ml centrifuge
tube with a 5mm steel bearing (Qiagen) and 1ml Trizol (Life Technologies). Samples were
loaded into a TissueLyser LT (Qiagen) and pulsed at 50 Hz for 5 minutes. RNA was then
extracted from the lung homogenate using a PureLink RNA Mini Kit (Life Technologies) and
first strand cDNA generated using a SuperScript First-Strand Synthesis System (Life Technolo-
gies) using oligoDT primers according to the manufacturer’s instructions. PCR was then con-
ducted using Fast SYBR Master Mix (Life Technologies) according to the manufacturer’s
instructions and specific primers (sequence available on request). Expression was normalized
to expression of the TATA-binding protein.
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Capsular thickness
Capsular thickness was determined by Alexa fluor 488 dextran exclusion microscopy as previ-
ously described [52]. Transmission electron microscopy was performed using ruthenium red
to preserve the capsule as previously described [53].
Neutrophil phagocytosis, killing and NET formation
Mouse neutrophils were obtained by induction of peritonitis by injection of 9% Casein [54].
Human neutrophils were obtained from whole blood by density centrifugation as previously
described [55]. Phagocytosis and killing studies were performed as previously described [56].
Additionally, neutrophil phagocytosis was quantified by flow cytometry and confocal micros-
copy by incubating neutrophils with bacteria stained with 10μ eFluor 450 Proliferation Dye.
To assess NET formation, human neutrophils were seeded in RPMI 1640 medium supple-
mented with 2% heat inactivated human serum onto sterile, round glass coverslips placed in
24 well tissue culture plates. Neutrophils were infected with bacterial strains stained with
eFluor 450 as previously described or activated with 1μg/ml PMA as a positive control and
incubated at 37˚C under 5% CO2 for 4 hours. Neutrophils were fixed in 4% paraformaldehyde
in PBS for 60 minutes before being removed from tissue culture plates with curved forceps and
washed three times by inversion onto a drop of PBS on a parafilm sheet. Neutrophils were
then permeabilised, blocked and stained with anti-neutrophil elastase (rabbit polyclonal IgG,
AbCam) and SYTOX Orange (ThermoFisher) as described above before coverslipping and
mounting with Fluoromount- G (eBioscience) and imaging with confocal microscopy.
Ethics statement
All animal experiments were carried out in strict accordance with UK Government Home
Office Regulations concerning animal experimentation under Project Licence PPL 60/4631 as
well as the Animal Experiments Review Board of the University of Glasgow. These regulations
adhere to the European Union regulations concerning the use of animals in scientific research
under Directive 2010/63/EU of the European Parliament as well as the Animals (Scientific Pro-
cedures) Act 1986 of the UK Parliament.
Statistics
Between group analyses were performed using t tests, one or two way ANOVA, Kruskal Wallis
test or Mann Whitney test as indicated. Survival curves were compared using the logrank test.
P values < 0.05 were taken as significant.
Supporting information
S1 Fig. Gene expression of known IL-17 target genes. Expression was assessed using
qRT-PCR of cDNA derived from lung RNA extract (n = 3/group). Columns are means of
expression levels relative to wild type control animals; error bars are sem. Significance levels by
two sample t test are shown: (: P< 0.05, : P< 0.01, : P< 0.001).
(TIF)
S2 Fig. Change in body weight 24 hours after infection with TIGR4. Each point is an indi-
vidual animal; line shows median. Differences between the medians were assessed by Mann
Whitney test ( p< 0.01).
(TIF)
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S3 Fig. Lung wet/dry mass ratio 24 hours after infection with TIGR4. Each point is an indi-
vidual animal; line shows median. Differences between the medians were assessed by Mann
Whitney test (ns = not significant).
(TIF)
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